Actively Recruiting
Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy
Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-02-02
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 68Ga-DOTATATE digital PET/CT imaging in diagnosing soft tissue sarcomas. This study aims to assess the feasibility and potential clinical benefits of this imaging method, which may improve image quality compared to existing PET techniques. It also explores tumor uptake kinetics and the possibility of using imaging results to plan future peptide receptor radionuclide therapy for patients with specific tumor types. Participants receive an intravenous injection of gallium Ga 68-HA-DOTA-TATE and undergo digital PET/CT scanning for 60 minutes within two weeks after starting standard chemotherapy. About 24 hours later, they are given a fludeoxyglucose F-18 injection, followed by another 60-minute digital PET/CT scan. The study uses advanced PET detector technology to evaluate tumor characteristics and simulate imaging with lower doses or faster acquisition times. During the study, participants undergo imaging assessments to measure regions with increased tracer uptake. Researchers monitor safety by tracking adverse events up to seven days after imaging. The study involves standard chemotherapy alongside the imaging procedures. The total participation duration varies but includes the imaging sessions around chemotherapy and safety follow-up shortly after. This research is sponsored by Ohio State University Comprehensive Cancer Center.
CONDITIONS
Brief Title
68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older
- Diagnosed with any stage of soft tissue sarcomas and candidates for systemic therapies
- Have had one standard of care PET/CT scan within 30 days prior to enrollment at the study site
You will not qualify if you...
- Allergy or hypersensitivity to somatostatin or similar peptides
- Use of somatostatin long-acting analogs within the past 6 months
- Pregnant or breastfeeding women
- Currently incarcerated individuals
- Patients with acute infections
- Unable to complete investigational or standard imaging due to claustrophobia, radiation phobia, or other reasons
- Patients exceeding the weight limits or unable to fit in the PET/CT scanner due to body size
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 weeks after starting standard chemotherapy
Participants receive gallium Ga 68-HA-DOTA-TATE intravenously and undergo digital PET/CT imaging over 60 minutes up to two weeks after starting standard chemotherapy. About 24 hours after this imaging, participants receive fludeoxyglucose F-18 intravenously and undergo another digital PET/CT over 60 minutes.
2 visits (in-person)
Trial Site Locations
Total: 1 location
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here